Brivaracetam for Brain Tumor

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: University of Rochester

No Placebo Group

Approved in 5 Jurisdictions

Trial Summary

What is the purpose of this trial?

The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.

Eligibility Criteria

This trial is for adults over 18 with a specific type of brain tumor (diffuse astrocytic or oligodendroglial). Participants must be able to consent and not have had seizures before their diagnosis, nor can they be on seizure drugs. They should expect to live more than 6 months, not be pregnant, and have no severe liver or kidney disease.

Inclusion Criteria

Patients must be able to provide informed consent

I am over 18 and have been diagnosed with a specific brain tumor.

Exclusion Criteria

Pregnancy

My first sign of a brain tumor was a seizure.

I cannot swallow pills.

Participant Groups

The study is testing the tolerability and safety of Brivaracetam, a medication potentially useful for patients with brain tumors. It aims to see if people can handle the drug without significant issues.

Group I: Experimental Experimental Treatment 1 Intervention

Brivaracetam at a dose of 50 mg twice daily for 6 months

Brivaracetam is already approved in European Union, United States, Canada, Australia for the following indications:

🇪🇺 Approved in European Union as Briviact for:

• Partial-onset seizures with or without secondary generalisation

🇺🇸 Approved in United States as Briviact for:

• Focal (partial) onset seizures in epilepsy patients 1 month of age and older

🇨🇦 Approved in Canada as Brivlera for:

• Partial-onset seizures with or without secondary generalisation

🇦🇺 Approved in Australia as Briviact for:

• Partial-onset seizures with or without secondary generalisation

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

University of Rochester Medical Center Rochester, NY

Who Is Running the Clinical Trial?

University of Rochester Lead Sponsor

References